Related Experiment Video
Updated: Jun 26, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Negative regulation of SH2B3 by SMYD5 controls epithelial-mesenchymal transition in lung cancer
In Hwan Tae1, Tae Young Ryu1, Yunsang Kang2
1Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Republic of Korea.
Abstract:
The main cause of death in lung cancer patients is metastasis. Thus, efforts to suppress micrometastasis or distant metastasis in lung cancer, identify therapeutic targets and develop related drugs are ongoing. In this study, we identified SET and MYND domain-containing protein 5 (SMYD5) as a novel metastasis regulator in lung cancer and found that SMYD5 was overexpressed in lung cancer based on both RNA-sequencing analysis results derived from the TCGA portal and immunohistochemical analysis results; knockdown of SMYD5 inhibited cell migration and invasion by changing epithelial-mesenchymal transition markers and MMP9 expression in NCI-H1299 and H1703 cell lines. Additionally, SMYD5 knockdown increased Src homology 2-b3 expression by decreasing the level of H4K20 trimethylation. Furthermore, in an in vitro epithelial-mesenchymal transition system using TGF-β treatment, SMYD5 knockdown resulted in reduced cell migration and invasion in the highly invasive NCI-H1299 and H1703 cell lines. Based on these findings, we propose that SMYD5 could serve as a potential therapeutic target for lung cancer treatment and that cotreatment with an SMYD5 inhibitor and chemotherapy may enhance the therapeutic effect of lung cancer treatment.
Insights
Lung cancer metastasis is a major cause of death. Researchers identified SET and MYND domain-containing protein 5 (SMYD5) as a key regulator of lung cancer metastasis, suggesting it as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Metastasis is the primary cause of mortality in lung cancer patients.
- Identifying novel therapeutic targets to inhibit metastasis is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the role of SET and MYND domain-containing protein 5 (SMYD5) in lung cancer metastasis.
- To evaluate SMYD5 as a potential therapeutic target for lung cancer treatment.
Main Methods:
- RNA-sequencing analysis using TCGA data and immunohistochemical analysis to assess SMYD5 expression in lung cancer.
- SMYD5 knockdown experiments in NCI-H1299 and H1703 cell lines to evaluate effects on cell migration and invasion.
- Analysis of epithelial-mesenchymal transition markers, MMP9, Src homology 2-b3, and H4K20 trimethylation levels.
- In vitro epithelial-mesenchymal transition induction using TGF-β.
Main Results:
- SMYD5 was found to be overexpressed in lung cancer tissues.
- Knockdown of SMYD5 significantly inhibited cell migration and invasion in lung cancer cell lines.
- SMYD5 knockdown altered epithelial-mesenchymal transition markers and MMP9 expression.
- SMYD5 knockdown led to increased Src homology 2-b3 expression by decreasing H4K20 trimethylation.
- SMYD5 inhibition reduced cell migration and invasion in a TGF-β-induced EMT model.
Conclusions:
- SMYD5 is identified as a novel regulator of lung cancer metastasis.
- SMYD5 represents a potential therapeutic target for lung cancer.
- Combination therapy with SMYD5 inhibitors and chemotherapy may enhance treatment efficacy.
Related Concept Videos
TGF - β Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation
Hedgehog Signaling Pathway
Negative Regulator Molecules
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...

